Neuroscience
Neuroscience
Mood
Areas of Interest
Treatment Resistant Depression – Major Depressive Disorder with inadequate response to 2 or more antidepressants
- Definition, patient identification, patient characteristics
- Evidence based-treatment paradigms
- Mechanistic rationale to treatment approaches
- Current and future disease management trends
- Innovation and technology for disease management
- Disease burden and overcoming treatment access challenges
- Impact in underserved communities and populations
- Allied health professional’s role in the disease management
Multiple Sclerosis
Areas of Interest
- Disease state education
- Patient and caregiver education on disease and disease management
- Brain volume loss
- Racial healthcare disparities in patients with MS
- Updates on current therapeutic options and treatment paradigms
- S1Ps (early use, rapid reversibility, discontinuations, MOA, drug interactions, vaccination)
- DMTs (switching, subgroup responsiveness, use in pregnancy, vaccination)
- Allied Health Profession's role in management of patients with MS
- COVID-19
Schizophrenia
Areas of Interest
- Antipsychotic long acting injectables (LAI) transition of care models (inpatient to outpatient)
- First-Episode Psychosis – Model of Care for introducing atypical antipsychotic LAIs early in treatment, including patient engagement strategies addressing acceptance and satisfaction
- Outcomes measures - Earlier use of atypical antipsychotic LAIs in early use psychosis clinics (clinical and psychosocial outcomes)
- Patterns of atypical antipsychotic LAI utilization in underserved communities and populations
- Effects and dynamics of the treatment coalition in adopting atypical antipsychotic LAI utilization earlier in schizophrenia treatment journey
- Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs
Certificate Of Separation
Please click here to view the certificate of separation
Click here to submit an Independent Medical Education Grant